Peripherally restricted CB1 receptor antagonist: Research advances
10.13220/j.cnki.jipr.2014.05.009
- Author:
Feng-Chun SHUI
1
Author Information
1. School of Life Sciences and Biopharmaceutical Sciences, Shenyang Pharmaceutical University
- Publication Type:Journal Article
- Keywords:
Antagonist;
Blood-brain-barrier;
Cannabinoid 1 receptor (CB1R);
Peripherally restricted
- From:
Journal of International Pharmaceutical Research
2014;41(5):552-558
- CountryChina
- Language:Chinese
-
Abstract:
Cannabinoid 1 receptor (CB1R) is one of most important targets for the treatment of obesity. However, the clinical application of CB1R antagonist rimonabant is restricted because of the central nervous system-related unwanted liabilities. Peripherally restricted CB1R antagonist with limited blood-brain-barrier penetration may maintain the antiobesity efficacy of rimonabant without unwanted side effects. This strategy has become the new hot spot for the development of antiobesity drugs. In this paper, we review the recent progress in peripherally restricted CB1 receptor antagonist.
